165 related articles for article (PubMed ID: 36541037)
1. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes.
Heise T; Chien J; Beals JM; Benson C; Klein O; Moyers JS; Haupt A; Pratt EJ
Diabetes Obes Metab; 2023 Apr; 25(4):1080-1090. PubMed ID: 36541037
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
Frias J; Chien J; Zhang Q; Chigutsa E; Landschulz W; Syring K; Wullenweber P; Haupt A; Kazda C
Lancet Diabetes Endocrinol; 2023 Mar; 11(3):158-168. PubMed ID: 36758572
[TBL] [Abstract][Full Text] [Related]
3. Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial.
Bue-Valleskey JM; Kazda CM; Ma C; Chien J; Zhang Q; Chigutsa E; Landschulz W; Haupt A; Frias JP
Diabetes Care; 2023 May; 46(5):1060-1067. PubMed ID: 36944059
[TBL] [Abstract][Full Text] [Related]
4. Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes.
Kazda CM; Bue-Valleskey JM; Chien J; Zhang Q; Chigutsa E; Landschulz W; Wullenweber P; Haupt A; Dahl D
Diabetes Care; 2023 May; 46(5):1052-1059. PubMed ID: 36920867
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein.
Moyers JS; Hansen RJ; Day JW; Dickinson CD; Zhang C; Ruan X; Ding L; Brown RM; Baker HE; Beals JM
J Pharmacol Exp Ther; 2022 Sep; 382(3):346-355. PubMed ID: 35840338
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes.
Hövelmann U; Engberg S; Heise T; Kristensen NR; Nørgreen L; Zijlstra E; Ribel-Madsen R
Diabetes Obes Metab; 2024 May; 26(5):1941-1949. PubMed ID: 38379002
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 2 diabetes.
Pieber TR; Asong M; Fluhr G; Höller V; Kristensen NR; Larsen JH; Ribel-Madsen R; Svehlikova E; Vinther S; Voortman M; Haahr H
Diabetes Obes Metab; 2023 Dec; 25(12):3716-3723. PubMed ID: 37694740
[TBL] [Abstract][Full Text] [Related]
9. The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa.
Rosenstock J; Juneja R; Beals JM; Moyers JS; Ilag L; McCrimmon RJ
Endocr Rev; 2024 May; 45(3):379-413. PubMed ID: 38224978
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Addy C; Tatosian D; Glasgow XS; Gendrano IN; Kauh E; Martucci A; Johnson-Levonas AO; Selverian D; Matthews CZ; Gutierrez M; Wagner JA; Aubrey Stoch S
Clin Ther; 2016 Mar; 38(3):516-30. PubMed ID: 26869191
[TBL] [Abstract][Full Text] [Related]
11. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.
Schmitt C; Portron A; Jadidi S; Sarkar N; DiMarchi R
Diabetes Obes Metab; 2017 Oct; 19(10):1436-1445. PubMed ID: 28730694
[TBL] [Abstract][Full Text] [Related]
13. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
14. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).
Rosenstock J; Hollander P; Bhargava A; Ilag LL; Pollom RK; Zielonka JS; Huster WJ; Prince MJ
Diabetes Obes Metab; 2015 Aug; 17(8):734-41. PubMed ID: 25931141
[TBL] [Abstract][Full Text] [Related]
15. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
King AB
Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
[TBL] [Abstract][Full Text] [Related]
16. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
17. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
[TBL] [Abstract][Full Text] [Related]
18. Frequency and Severity of Hypoglycemia Under Conditions of Increased Hypoglycemic Risk with Insulin Efsitora Alfa Versus Insulin Glargine Treatment in Participants with Type 2 Diabetes.
Heise T; Andersen G; Pratt EJ; Leohr J; Fukuda T; Wang Q; Kazda C; Bue-Valleskey JM; Bergenstal RM
Diabetes Ther; 2024 Jun; ():. PubMed ID: 38907935
[TBL] [Abstract][Full Text] [Related]
19. Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.
Harris C; Forst T; Heise T; Plum-Mörschel L; Watkins E; Zhang Q; Fan L; Garhyan P; Porksen N
Diabetes Technol Ther; 2017 Aug; 19(8):463-470. PubMed ID: 28817342
[TBL] [Abstract][Full Text] [Related]
20. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Rosenstock J; Park G; Zimmerman J;
Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
